Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012

Swallow, Elyse; Zhang, Jie; Thomason, Darren; Tan, Ruo-Ding; Kageleiry, Andrew; Signorovitch, James

doi:10.1185/03007995.2014.908829

Cited by 60 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When palliative ET was administered, the patients received a median of 2 lines of ET. This result is in line with those reported in previous studies [13,14]. The median duration of ET was 18 months.…”

Section: Discussionsupporting

confidence: 83%

“…Of some younger patients (12% of the cohort), nearly all had had prior adjuvant ET, and most of them had visceral metastases at first diagnosis of metastatic disease, so that the attending oncologists subsequently had no confidence in further ET lines and only chemotherapy was used during the further palliative disease course. Previous clinical practice studies analyzing palliative therapy in HR-positive BC excluded patients who had no systemic therapy and analyzed only those who received a therapy [10,11,12,13,14]. However, in order to describe the entity HR-positive metastatic BC accurately and comprehensively, it is important to also report the cases in which systemic therapies had not been used.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?

Güth

Huang²,

Schötzau³

et al. 2015

Oncology

View full text Add to dashboard Cite

Background: This study provides real-world clinical evidence regarding palliative endocrine therapy (ET) in breast cancer (BC). The main questions to be answered were: how often and how long did patients receive ET? A particular aspect was the analysis of compliance and persistence with ET. Methods: An analysis of a nonselected/consecutive cohort of women with distant metastatic hormone receptor-positive BC (n = 205) was conducted. Results: In all, 165 patients (80.5%) received ET during the palliative disease course. The noncompliance rate was 1.5%. Sixty-seven patients (40.6%) had ET as the only antineoplastic therapy. The median number of therapy lines was 2, and the median duration was 18 months. The median metastatic disease survival (MDS) was 34 months. In patients who had an MDS of ≥9 months (n = 145; 87.9%), during 70.6% of the MDS time only ET had been administered. Patients who were naïve to ET more often had a good response to and a longer duration of palliative ET than those who were not. The nonpersistence rate was 4.3%. Conclusions: Excluding the few patients who had a rapidly progressive course, the disease was controlled for about 70% of the entire palliative disease course with ET alone. Only very few patients were nonpersistent with ET and consciously stopped a still effective, ongoing ET.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?

Güth

Huang²,

Schötzau³

et al. 2015

Oncology

View full text Add to dashboard Cite

show abstract

“…The authors observed that few patients received three lines of endocrine therapy as suggested by NCCN guidelines, and concluded that single-agent endocrine therapy may not be as effective beyond first line, given most patients received less than three lines of endocrine therapy before receiving chemotherapy and the median future science group www.futuremedicine.com duration of endocrine therapy decreased from first to second line. Swallow et al [35] evaluated the real-world patterns of endocrine therapy for HR-positive/HER2-negative mBC in 19,120 postmenopausal mBC patients in the USA from 2002 to 2012. The authors examined mean numbers of lines of therapy and median duration of each line using the MarketScan commercial health insurance claims database (2002Q3-2012Q2).…”

Section: Overview Of Treatment Patterns Studiesmentioning

confidence: 99%

“…Ten of these were retrospective chart reviews [29,30,[32][33][34]37,38,41,44,45], two were physician surveys [31,46] and six were analyses of secondary databases (e.g., Surveillance, Epidemiology and End Results [SEER]-Medicare database, commercial claims) [35,36,39,40,42,43]. These studies examined a variety of therapeutic options, including endocrine therapy, chemotherapy and surgery.…”

Section: Overview Of Treatment Patterns Studiesmentioning

confidence: 99%

Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review

Parisi¹,

Pelletier²,

Cherepanov

et al. 2018

J. Comp. Eff. Res.

View full text Add to dashboard Cite

Aim:With the aggregation of real-world data in healthcare, opportunities for outcomes research are growing. In this study, we summarize published literature examining comparative effectiveness research (CER), treatment patterns, quality of life (QoL) and costs in HER2-negative and triple-negative (TN) metastatic breast cancer (mBC). Methods: PubMed (2010-January 2016) and four conferences (2013-January 2016) were searched using MeSH/keywords, including mBC, QoL, morbidity and therapeutics. Studies relating to CER, treatment patterns, QoL, costs or treatment appropriateness in US patients with HER2-negative/TN mBC were included in the review. Results: Of 1782 identified records, 33 studies met full inclusion criteria: seven related to CER, 18 to treatment patterns, one to treatment appropriateness/navigation, two to QoL and five to costs. Studies varied in objectives, designs and outcomes. Study designs included retrospective chart reviews (52%), retrospective secondary database analyses (27%), economic models (12%), physician surveys (6%) and patient surveys (3%). 25 studies reported results on HER2-negative mBC, six on TN mBC and two on both subtypes. The most common end points examined were treatment patterns, overall survival and progression-free survival. Conclusion: Outcomes research in HER2-negative mBC in the USA was limited, specifically among TN patients, indicating an opportunity for further research in this high unmet need population. Endpoints and treatment options varied, thus, it is difficult to draw summary conclusions about these studies. Outcomes research examining real-world data in mBC has increased in recent years, and may continue to grow with the implementation of new policy programs. Breast cancer is the most common cancer type among women in the USA. 29% of incident cancer cases are attributable to breast cancer alone [1]. About 66% of women with breast cancer have HER2-negative and 10-17% have HER2-negative, estrogen receptor-negative (ER-negative) and progesterone receptor-negative (PR-negative) cancer, referred to as triple-negative breast cancer (TNBC) [2,3]. In 2016, an estimated 246,660 women were newly diagnosed with breast cancer, of which approximately 6% had metastatic or stage IV disease at the time of diagnosis [1,4,5]. About 30% of women initially diagnosed with early-stage breast cancer develop recurrent advanced or metastatic disease [6,7]. The 5-year survival rate with stage IV breast cancer is only 26.3% [4,5].Tumor markers in breast cancer impact prognosis, treatment and survival [8]. Prognosis has improved significantly for patients with metastatic HER2-positive breast cancer with emergence of trastuzumab and other anti-HER2 agents but has lagged for patients with advanced HER2-negative breast cancer since the emergence of effective new targeted therapies such as everolimus is only beginning [9]. Moreover, an important minority of these patients, those with triple-negative (TN) disease, has a relatively poor prognosis given the lack of targeted therapies, leaving cytoto...

show abstract

“…A retrospective chart review of patients with recurrent or de novo HR-positive/HER2-negative MBC, treated at 13 oncology practices in the US, found that ET was used as first-line treatment in only 68%, and only about 7% received 3 lines of ET before chemotherapy was initiated [11] . Another analysis of 19,120 women with HR-positive/HER2-negative MBC reported that only 60% received initial ET and only 26% received secondline ET [12] . This article reviews approved and emerging ET options and available data regarding their impact on QoL in patients with HR-positive MBC, including those with visceral disease.…”

mentioning

confidence: 99%

Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations

Chalasani

2017

Oncology

View full text Add to dashboard Cite

The treatment landscape for hormone receptor-positive metastatic breast cancer continues to evolve as the molecular mechanisms of this heterogeneous disease are better understood and targeted treatment strategies are developed. Patients are now living for extended periods of time with this disease as they progress through sequential lines of treatment. With a rapidly expanding therapeutic armamentarium, the prevalence of metastatic breast cancer patients with prolonged survival is expected to increase, as is the duration of survival. Practice guidelines recommend endocrine therapy alone as first-line therapy for the majority of patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The approval of new agents and expanded combination options has extended their use beyond first line, but endocrine therapy is not used as widely in clinical practice as recommended. As all treatments are palliative, even as survival is prolonged, optimizing and maintaining patient quality of life is crucial. This article surveys data relevant to the use of endocrine therapy in the setting of hormone receptor-positive metastatic breast cancer, including key clinical evidence regarding approved therapies and the impact of these therapies on patient quality of life.

show abstract

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012

Cited by 60 publications

References 25 publications

Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?

Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?

Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review

Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations

Contact Info

Product

Resources

About